Short chain fatty acids (SCFAs) play a central role in health and disease.
Introduction
Short chain fatty acids (SCFAs) play a critical role as mediators of health and disease. [1] [2] [3] For example, butyrate stimulates differentiation in many cellular models of cancer [4] [5] and displays context-dependent effects on tumorigenesis [6] [7] [8] and immune cell function [9] [10] in whole organisms. In addition to their role in acetylcoenzyme A (CoA) biosynthesis via the β-oxidation pathway and activity as histone deacetylase (HDAC) inhibitors [11] [12] [13] , SCFAs also constitute the requisite precursor for protein short chain fatty acylation. This family of posttranslational modifications (PTMs) derives from the metabolism of SCFAs to acyl-CoAs, which may then be used as cofactors by lysine acetyltransferase (KAT) enzymes ( Figure 1 ). [14] [15] [16] Due to the unique reliance of short chain fatty acylation on both metabolism and KAT activity, this PTM has significant potential to provide insights into the role of these pathways in disease. However, few methods for studying short chain fatty acylation exist. Antibody-based analyses of these modifications are limited by the poor affinity and selectivity of antibodies generated against marks such as butyryl-and propionyl-lysine. This may be why these approaches have, to date, identified only a handful of short chain fatty acylated targets. [17] [18] [19] Bioorthogonal metabolic tracing has emerged as an alternative, unbiased strategy for monitoring SCFA-derived acylation. [20] [21] Pioneered by Hang and coworkers, this approach monitors short chain fatty acylation by using alkynyl-SCFAs to introduce a latent affinity handle into SCFAmodified proteins, enabling their facile visualization and enrichment. 22 A challenge of this approach is that bioorthogonal SCFA tracers must compete with endogenous SCFAs for metabolism and KAT utilization, potentially limiting their efficacy. Thus, the development of highly sensitive bioorthogonal reporters for profiling short chain fatty acylation remains an important goal.
A validated strategy to increase the cellular delivery of small molecules and metabolic tracers is through reversible masking of polar functional groups. [23] [24] [25] Regarding SCFAs specifically, a number of groups have found butyrate's biological effects to be increased upon masking its polar carboxylate moiety with an ester. [26] [27] In analogy with pro-drugs, we refer to such molecules as "prometabolites." 28 A prototypical SCFA pro-metabolite is tributyrin, a naturallyoccurring butyrate ester that displays potent antineoplastic and chemopreventative activity. 29 Inspired by tributyrin and other pro-metabolites, we hypothesized that masking the polar carboxylate of bioorthogonal SCFAs may similarly increase their potency. Such optimized agents have the potential to provide a robust reporter of short chain fatty acylation, and by proxy, metabolism and cellular KAT/KDAC activity. Towards the goal of defining acylationdependent signaling in cancer, here we report a bioorthogonal pro-metabolite strategy for profiling short chain fatty acylation ( Figure 1 ). First, we systematically define the influence of SCFA-ester linkage and bioorthogonal chemotype on cellular protein labeling. Next, we demonstrate the ability of optimized agents to form bioorthogonal acyl-CoAs in cells and establish their cell-type and metabolism-specific labeling properties. Finally, we demonstrate the utility of bioorthogonal pro-metabolites to identify novel targets of SCFAs in cells. These studies highlight the power of pro-metabolite approaches to expand the scope of bioorthogonal metabolic tracing methods, and suggest novel strategies for studying the signaling role of short chain fatty acids in health and disease.
Results and discussion

Design of a bioorthogonal pro-metabolite library.
To identify sensitive agents for profiling short chain fatty acylation, we focused on exploring three structural elements of bioorthogonal SCFAs ( Figure 2 ). First we varied the bioorthogonal reporter, reasoning azides (1-8) and alkynes (9-16) may demonstrate differential metabolic processing and detection sensitivities. Second, we varied the length of the alkyl chain between the SCFA carboxylate and bioorthogonal reporter. Previous studies have found SCFA chain length to be a crucial factor in the formation of SCFA-CoAs by acyl-CoA synthetases, 30-32 and the utilization of these SCFA-CoAs by KATs. 15, 33 Third, we varied the carboxylate ester moiety. Here we focused on simple ethyl esters (2, 6, 10, 14), as well as carnitine and triacylglycerol esters ( Figure 2 ). Carnitine esters (3, 7, 11, 15) were designed to facilitate delivery of SCFAs to the mitochondria, an organelle that shows robust acyl-CoA metabolism. 34 In contrast, tributyrin-inspired triacylglycerol esters (4, 8, 12, 16) were designed to take advantage of the known increased cellular uptake of highly lipophilic molecules, as well as the ability of these esters to be specifically cleaved by endogenous triacylglycerol lipases. An additional advantage of these molecules relative to other esters is their ability to enable suprastoichiometric delivery (three equivalents) of their cognate bioorthogonal SCFAs. This panel of pro-metabolites was readily synthesized using straightforward ester bond formation from the parent bioorthogonal carboxylates (Scheme S1). While the majority of bioorthogonal SCFA derivatives were obtained in good yield, we found carnitine esters to be the most difficult targets due to their challenging purification. Similar optimization was required to obtain triacylglycerol SCFAs, as literature conditions yielded a complex mixture of mono-, di-, and triacylglycerides. These studies establish a systematic panel of bioorthogonal SCFAs to define the structure-activity relationship of prometabolites in living cells.
Evaluation of bioorthogonal pro-metabolites for in vitro protein labeling.
With these compounds in hand, we next evaluated our library for protein labeling in HepG2 human hepatocellular carcinoma cells ( Figure 3 ). Our choice of liver cancer as a model for evaluation of our pro-metabolites stems from the fact that the liver is a major site of SCFA metabolism in vivo, where it utilizes abundant acyl-CoA synthetase activities to transform SCFAs into acyl-CoAs that support short chain fatty acylation. 35 Accordingly, we treated HepG2 cells with each of our pro-metabolites at a single concentration for 24 hours. Cells lysates were harvested, subjected to click chemistry with a fluorescent azide or alkyne, and analyzed by SDS-PAGE ( Figure 3a ). Consistent with previous reports, detection of azide-labeled proteins using a fluorophore alkyne manifested uniformly higher background labeling. 36 Pro-metabolites demonstrating the most intense protein labeling profiles were the bioorthogonal triacylglycerides (4, 8, 12, 16) as well as ethyl azidopropionate (6) was accompanied by noticeable toxicity at 24 hours ( Figure S1a ). Interestingly, analysis of the bioorthogonal alkyne series revealed pentynoate esters to be consistently more toxic than their hexynoate counterparts ( Figure S1b ). This did not correlate with protein labeling or HDAC inhibitory activity, (Figure 3 , S2), suggesting pentynoate may manifest its toxic affects through alternative mechanisms. Of note, 5-pentynoic acid structurally resembles 5-pentenoic acid, a cytotoxic agent known to form electrophilic species and inhibit fatty acid oxidation in cells. 37 Figure S3 ). To our knowledge this represents first direct evidence of bioorthogonal acyl-CoA formation in living cells. These data, combined its facile synthesis, prompted us to further evaluate 6 as an optimized reporter of cellular short chain fatty acylation.
Mechanistic analysis of a lead pro-metabolite for short chain fatty acylation profiling.
To better define the activity of pro-metabolite 6, we next evaluated it in a series of experiments using our fluorescent gel-based assay. Cellular labeling of proteins by 6 was dose-dependent, with significant labeling observed at concentrations as low as 0.5 mM (Figure 4a ). Analyzing the time-dependent activity of 6 found labeling to peak between 6 and 9 hours ( Figure S1d ). Of note, the reduced labeling observed at 24 hours suggests short chain fatty acylation implemented by 6 may be reversible, consistent with the known ability of many HDAC enzymes to deacetylate fatty acyl-lysine derivatives. [38] [39] To assess the generality of prometabolite 6, we compsared cell labeling in HepG2 to labeling in cell lines derived from a variety of tissues of origin, including lung (A549) and kidney (HEK-293).
Interestingly, each cell line demonstrated intense, but unique, patterns of protein labeling by 6 ( Figure 4b ). This suggests the ability of 6 to function as a useful reporter of short chain fatty acylation in a number of tissues and cell types.
Next, we sought to better understand the metabolic determinants of short chain fatty acylation by 6 ( Figure 5 ). First, we explored whether labeling of proteins by 6 was sensitive to competition by endogenous short chain fatty acids such as acetate. Our hypothesis was that acetate may compete with 6 for acyl-CoA synthetase active sites, 35 thereby reducing bioorthogonal acyl-CoA biosynthesis and competing for sites of protein labeling (Figure 5a ). Consistent with this hypothesis, we observed decreased labeling of cellular proteins by 6 upon coadministration of acetate ( Figure 5b ). Next, we tested the effect of media glucose on labeling on short chain fatty acylation by 6. Previous studies have found that depriving cells of glucose causes increased utilization of SCFAs for energy production via fatty acid oxidation. 6 Importantly, this bioenergetic shift requires increased biosynthesis of SCFA-CoAs, and should therefore increase labeling by 6 ( Figure 5a ) Indeed, we observed increased labeling of cellular proteins by 6
when cells were grown in low glucose compared to nutrient replete media ( Figure   5c ). Finally, we explored the impact of acetylation dynamics on metabolic labeling. Due to the lack of well-validated chemical probes of KAT enzymes, [40] [41] we focused on assessing how labeling of proteins by 6 was impacted by HDAC inhibitors. Treatment of cells with the HDAC inhibitor SAHA was found to upregulate global acetylation, while coordinately decreasing labeling of cellular proteins by 6 ( Figure 5d ). This indicates active deacetylation may be required to liberate lysines for short chain fatty acylation by bioorthogonal acyl-CoAs. These studies define pro-metabolite 6 as a general reporter of SCFA metabolism and acylation.
Profiling the cellular targets of bioorthogonal SCFAs.
Finally, we sought to demonstrate the ability of 6 to identify specific targets of short chain fatty acylation in living cells. As a proof-of-concept, we exposed human embryonic kidney cells to either a pulse of 6 or vehicle DMSO for six hours. Following isolation of cell lysates, proteins labeled by 6 were chemoselectively ligated to a biotin alkyne via Cu-catalyzed [3+2] cycloaddition, and enriched over streptavidin-agarose. Enriched proteins were subjected to an on-bead tryptic digest and identified by LC-MS/MS. Candidate short chain fatty acylation targets were defined as proteins enriched greater than 2-fold from cells treated with 6, relative to a vehicle control (Table S1 ). Analyzing the abundance of these targets via spectral counting identified 447 low abundance proteins (1-5 spectral counts), 121 medium abundance proteins (5-10 spectral counts), and 91 highly abundant proteins (>10 spectral counts). Of note, many of these proteins, including 41% of highly abundant enriched proteins, have previously been identified as targets of short chain fatty acylation by Hang and coworkers (Table   S1 ). 22 Gene ontology analysis also supported the utility of 6 as a bioorthogonal reporter, with acetylation being the most strongly enriched term (P = 1.5 x 10 -153 ) (Table S2 ). This analysis also revealed targets of 6 were enriched in nuclear proteins, consistent with the nuclear localization of many KATs (Table S3 ). Of note, KATs identified in triplicate datasets include EP300, which has previously been observed to catalyze short chain fatty acylation. EP300 may be a target of this modification via autoacetylation. 17, [42] [43] [44] [45] We defer a more detailed validation and discussion of these candidate SCFA targets for future studies. However, overall these findings support the ability of 6 to be applied in global proteomic studies of short chain fatty acylation.
Conclusions
Here we have described a bioorthogonal pro-metabolite strategy for profiling cellular short chain fatty acylation. Specifically, we find that several alkyne-and azide-SCFAs function as effective protein labeling reagents when delivered as triglyceride analogues (4, 8, 12, 16 ), or as ethyl esters (6) . Detailed characterization of lead pro-metabolite 6 found that it can form bioorthogonal acyl-CoAs in cells, is active in several cell models, and labels proteins in a manner reflective of cellular metabolism and acetylation dynamics. Our studies suggest that pro-metabolite strategies, which have previously been used to optimize incorporation of azide-and alkyne-containing glycans, [24] [25] may have broad utility in the delivery of bioorthogonal metabolic tracers. Looking forward, we anticipate several applications for the specific SCFA pro-metabolites demonstrated here. First, the strong labeling afforded by 6 suggest it may be a useful in vivo tracer for identifying endogenously short chain fatty acylated proteins associated with SCFA-driven phenotypes such as differentiation, antiinflammation, or tumor suppression. 4, [6] [7] [8] [9] To be most impactful, such studies will require that pro-metabolites recapitulate the phenotypic effects of endogenous SCFAs. As many of these effects have been associated with the HDAC activity of SCFAs, it is promising that our cellular studies indicate the azido-and alkynyl-SCFAs investigated here also stimulate histone acetylation ( Figure S2 ). Second, bioorthogonal pro-metabolites may provide a facile readout of global KAT/KDAC activity in cellular or in vivo systems, complementing current chemical proteomic approaches, which are only applicable in cell lysates. [46] [47] Finally, bioorthogonal SCFA pro-metabolites may facilitate chemical genetic approaches to identify specific KAT substrates in cells. 48 Of note, mutations have been reported that confer KAT2A (GCN5L2) and KAT8 (MOZ) with the ability to use elongated azido-and alkynyl-CoAs. 49 Overall, these studies represent a key methodological advance in the development of new methods to understand acetylationdependent signaling in living systems.
Methods
General synthetic procedures and materials
Chemicals were purchased from commercial sources (Sigma-Aldrich, Alfa Aesar, and TCI America) and used without further purification unless otherwise noted. 2azidoacetate (1), ethyl azidoacetate (2), 4-pentynoic acid (9) , ethyl pentynoate (10), hexynoic acid (13) , and ethyl hexynoate (14) were obtained commercially. 3azidopropionic acid (5), carnitine esters (3, 7, 11, 15 ) and glycerol esters (4, 8, 12, 16) were prepared according to literature procedures. 50 
General procedures and materials for cellular assays
A549 and HEK-293 cells were obtained from the NCI Tumor Cell Repository, while
HepG2 cells were obtained from ATCC (Manassas VA). All cell lines were cultured at 37 °C under 5% CO 2 atmosphere in a growth medium of RPMI supplemented with 10% FBS and 2 mM glutamine, with the exception of HEK293T cell lines, which were cultured in DMEM supplemented with 10% FBS, 2 mM glutamine. Cells were harvested by scraping and cell lysates prepared by sonication as previously described. 53 Protein concentrations were determined by Qubit Protein Assay kit (Life Technologies #Q33212). Fluorescent labeling analyses were performed via Cu-catalyzed ligation to a TAMRA-azide or alkyne as previously described. 46 54 SILEC experiments were performed as previously described. Acyl-CoAs were isolated by acid extraction and analyzed by LC-MS as previously described. [55] [56] 3-azidopropionyl-CoA was synthesized and purified by standard methods, 53, 57 and used as a standard in LC-MS analyses. Histones were isolated by acid extraction and analyzed by immunoblotting as previously described. 33, 58 Toxicity of pro-metabolites were assessed by sulforhodamine B staining 59 after treatment for the dose/duration indicated. For proteomic analyses, HEK-293 proteomes (8 mg per replicate, treated with 6 or vehicle DMSO) were ligated to a biotin-alkyne using Cu-catalyzed [3+2] cycloaddition. 46, 60 Enrichment, tryptic digest, LC-MS/MS analyses, and database searching was performed as previously described. 46
Treatment of cells with pro-metabolites for metabolic labeling analyses
For labeling experiments, cell lines were plated and allowed to adhere overnight. Cells were then treated with pro-metabolites 1-16 by adding of DMSO stock solutions directly to growth medium at the specified concentration, followed by gentle agitation and incubation for the specified time. For low glucose experiments, cells were grown in DMEM supplemented with 1 mM glucose (prepared from glucose-free media) for 24 h prior to addition of pro-metabolite 6. For acetate and SAHA experiments, acetate (1 mM) or SAHA (10 μM) were added to media immediately prior to pro-metabolite 6. In all experiments, final DMSO concentrations were < 0.5%. Unfractionated proteomes were harvested by washing adherent cells (80-90% confluent) 3x with ice cold PBS, and scraping cells into a Falcon tube followed by centrifugation (500 rcf x 5 min, 4 °C).
Lysates were isolated from cell pellets by sonication as described above. Specific experimental treatment conditions are indicated in the figure captions.
Mass spectrometry characterization of azidopropionyl-CoA formation
Cellular formation of azidopropionyl-CoA was confirmed by LC-HRMS and LC-MS/HRMS using previously described methods. 61 Briefly, azidopropionyl-CoA 
